Purpose: The overexpression of hypoxia-inducible factor 1α (HIF-1α) is a common finding in
hepatocellular carcinoma (HCC), and it leads to angiogenesis and poor prognosis …

Primary liver cancer is the fifth most common cancer worldwide and the third most common
cause of death from cancer, resulting in more than 600,000 deaths per year. The major risk …

Early studies indicated that the androgen receptor (AR) might play key roles to impact
hepatocellular carcinoma (HCC) progression at different stages. Its linkage to hypoxia, a …

Abstract Background Aberrant activation of Axl is implicated in the progression of
hepatocellular carcinoma (HCC). We explored the biologic significance and preclinical …

Sorafenib, an antiangiogenic agent, can promote tumor invasion and metastasis. The
phosphatidylinositol 3-kinase (PI3K)/Akt/Snail-dependent pathway plays an important role in …

Sorafenib is a new standard treatment for patients with advanced hepatocellular carcinoma
(HCC). However, the survival benefit of this treatment is modest, partly owing to drug …

Sorafenib is effective for patients with advanced hepatocellular carcinoma (HCC) and
particularly for those who are unsuitable to receive life-prolonging transarterial …

Sorafenib—a broad kinase inhibitor—is a standard therapy for advanced hepatocellular
carcinoma (HCC) and has been shown to exert antifibrotic effects in liver cirrhosis, a …

Objective Tumor recurrence and metastasis is the most common cause of mortality in
hepatocellular carcinoma (HCC) patients. Despite positive results with vascular endothelial …

Abstract Background & Aims The study aimed to evaluate the tissue expression of molecules
involved in intracellular signalling pathways as predictors of response to sorafenib in …